ETFs positioned on Novo Nordisk A/S

Name Weight AuM 1st Jan change
21.31% 200 M€ -4.11% -
10.45% 4 M€ +15.15% -
5.4% 21 M€ -1.17% -
3.78% 0 M€ -.--% -
3.41% 0 M€ -.--% -
2.53% 0 M€ -.--% -
2.53% 0 M€ -.--% -
2.22% 0 M€ -.--% -
1.31% 0 M€ -.--% -
1.03% 9 M€ +11.81% -
1.02% 33,076 M€ +9.56% -
0.89% 1,022 M€ +18.16% -
0.79% 0 M€ -.--% -
0.76% 0 M€ -.--% -
0.75% 0 M€ -.--% -
0.57% 898 M€ +0.18% -
0.56% 0 M€ -.--% -
0.56% 0 M€ -.--% -
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).
Employees
77,406
More about the company
Trading Rating
Investor Rating
ESG MSCI
AAA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
442.95DKK
Average target price
676.63DKK
Spread / Average Target
+52.76%
Consensus

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
BENEFIT NOW